The global mycoplasma testing market reached approximately USD 1.02 billion in 2024 and is projected to grow at a CAGR around 10-13%, driven by biotech expansion, stringent contamination regulations, and rising cell‑culture R&D efforts
Market Overview
Mycoplasma are among the most prevalent contaminants found in cell culture systems, with the potential to significantly alter experimental results or lead to biopharmaceutical batch losses. The Mycoplasma Testing Market encompasses a range of detection methods used to identify these microorganisms in biological products, including PCR-based assays, ELISA, DNA staining, and microbial culture techniques.
Global Mycoplasma Testing Market size and share is currently valued at USD 1,064 million in 2024 and is anticipated to generate an estimated revenue of USD 2,909 million by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 13.4% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2023 – 2032.
The market is primarily driven by its applications across research laboratories, pharmaceutical and biotechnology companies, and contract research and manufacturing organizations. Due to strict regulatory frameworks and a rising emphasis on the purity and safety of biological products, mycoplasma testing is an indispensable step in drug manufacturing, gene therapy, and vaccine development.
𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
http://www.polarismarketresearch.com/industr…for-sample
Key Market Growth Drivers
Rising Biologics and Biosimilars Production
One of the foremost drivers for the Mycoplasma Testing Market is the rapid rise in biologics and biosimilars production. Biologics require stringent quality checks during manufacturing, as even a minute contamination can compromise product integrity. Mycoplasma contamination, in particular, is a major concern in biologics manufacturing due to its asymptomatic growth and resistance to standard antibiotics.
Increased R&D in Cell Culture Applications
The global research ecosystem is witnessing a shift toward more advanced therapies, including stem cell therapy, gene therapy, and monoclonal antibody development.
These advancements demand highly pure cell cultures, boosting the adoption of sensitive mycoplasma testing methods across laboratories and research institutions.
Stringent Regulatory Guidelines
Regulatory authorities across regions, including the FDA, EMA, and others, mandate strict quality control testing, including mycoplasma screening, for cell-derived products. The enforcement of these guidelines not only safeguards patients but also strengthens market demand for certified and validated testing technologies.
Advancements in Molecular Diagnostic Technologies
Modern molecular techniques such as real-time PCR and next-generation sequencing have transformed the landscape of mycoplasma testing. These methods offer quicker results, enhanced specificity, and improved detection limits, making them increasingly popular across commercial and academic settings.
Mycoplasma Testing Market Report Highlights
Rapid Growth Expected in Assays, Kits, & Reagents Segment: This segment is poised for the highest growth in the coming years, driven by the increasing demand for ready-to-use testing solutions that streamline laboratory workflows and improve efficiency. Nucleic Acid Amplification Technology (NAT) Leads Market Share: NAT emerged as the leading technology segment, owing to its ability to deliver rapid and accurate test results, making it a preferred choice for mycoplasma detection. Cell Line Testing Drives Revenue Expansion: The cell line testing segment is projected to account for a significant share of market revenue, fueled by the escalating production of biopharmaceuticals and the need to ensure product safety and integrity. Asia Pacific to Exhibit Fastest Growth: The Asia Pacific region is expected to register the most rapid growth throughout the forecast period, supported by increasing advancements in cell and gene therapy research and expanding biomanufacturing capabilities. Key Industry Participants: Prominent global companies operating in the mycoplasma testing market include leading developers and providers of advanced testing technologies and culture collections, contributing significantly to industry innovation and standardization.
Key Companies in the Mycoplasma Testing Market
Several leading companies are actively contributing to the evolution of the Mycoplasma Testing Market. They are engaged in launching innovative diagnostic tools, investing in R&D, expanding distribution networks, and entering strategic partnerships. These organizations are instrumental in advancing detection sensitivity, automating workflows, and reducing turnaround time.
Common key players include:
Agilent Technologies (US) American Type Culture Collection (US) Biological Industries Israel Beit Haemek Ltd. (Israel) Bionique Testing Laboratories, Inc. (US) Biotools B & M Labs, S.A. (Spain) Charles River Laboratories International, Inc. (US) Creative Bioarray (US) Eurofins Scientific (Luxembourg) GeneCopoeia, Inc. (US) GenBio (Canada) InvivoGen (US) Lonza Group Ltd. (Switzerland) Merck KGaA (Germany) Meridian Bioscience, Inc. (US)
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
http://www.polarismarketresearch.com/industr…ing-market
Market Segmentation
The Mycoplasma Testing Market can be segmented based on product type, technique, application, and end-user:
Mycoplasma Testing Market, Product & Service Outlook
Assays, Kits, & Reagents NAT assays, kits, & reagents ELISA assays, kits, & reagents Elimination Kits Stains Other assays, kits, & reagents Instruments Services
Mycoplasma Testing Market, Application Outlook
Cell line testing Virus Testing End-of-Production cell testing
Mycoplasma Testing Market, Technique Outlook
NAT ELISA Staining Other technique
Mycoplasma Testing Market, End User Outlook
Pharmaceutical & Biotechnology Companies Cell Banks & Laboratories Contract Research Organizations Academic Research Institutes
Access this Report:
http://www.polarismarketresearch.com/buy/737/0
Regional Analysis
The Mycoplasma Testing Market exhibits diverse growth dynamics across key regions, with North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa representing the major geographical segments.
North America
North America currently dominates the global market due to the strong presence of pharmaceutical and biotechnology industries, well-established research infrastructure, and favorable reimbursement scenarios. The region also benefits from proactive regulatory oversight and high investment in R&D initiatives related to biologics and cell therapies.
Europe
Europe is the second-largest regional market, characterized by a high adoption rate of advanced testing methodologies and stringent GMP (Good Manufacturing Practices) standards. Countries such as Germany, the UK, and France are witnessing increasing demand for contamination-free biologics and vaccines.
Asia Pacific
Asia Pacific is anticipated to experience the fastest growth during the forecast period. The surge is attributed to the expansion of biopharmaceutical manufacturing facilities in countries like China, India, and South Korea. Government initiatives to strengthen healthcare infrastructure and encourage biotechnology research also contribute to regional market growth.
Latin America and Middle East & Africa
While these regions hold a smaller market share, they present lucrative opportunities due to improving healthcare systems and growing pharmaceutical outsourcing. Investment in research hubs and increasing collaborations with global CROs and CMOs are expected to boost demand in these regions.
Conclusion
The global Mycoplasma Testing Market is set on a promising growth path, buoyed by escalating biologics development, stricter safety regulations, and cutting-edge diagnostic innovation. While some challenges remain in affordability and awareness, the overall outlook remains optimistic, with regional expansions and technology integration paving the way for a more resilient and responsive testing ecosystem. Stakeholders across the healthcare and life sciences spectrum must recognize mycoplasma testing not just as a regulatory requirement, but as a critical pillar of product quality and patient safety.
More Trending Report By Polaris Market Research:
Herceptin Biosimilars Market
High Level Disinfection Services Market
Human Organoids Market
Fitness Trackers Market
News From
Polaris Market Research &…
Category: Industry Reports & Market Analysis Profile: Polaris Market Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight and market intelligence to our customers across various industries. We at Polaris are obliged to serve our client base across the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, ch …
This email address is being protected from spambots. You need JavaScript enabled to view it.
For more information:
http://www.polarismarketresearch.com/industr…ons-market http://www.polarismarketresearch.com/industr…ure-market http://www.polarismarketresearch.com/industr…ing-market http://www.polarismarketresearch.com/industr…for-sample http://www.polarismarketresearch.com/buy/737/0 http://www.polarismarketresearch.com/press-r…ing-market
